Articles / Tracking & protocols
Tracking & protocols
Logging, schedules, inventory, and reading trends — the practical side.
How to track a peptide protocol
What to record when tracking a research protocol: doses, timing, sites, inventory, and markers — and why a written log beats memory. Education only.
Why log and rotate injection sites?
The rationale for tracking and rotating injection sites: why repeated use of one spot is a problem, and why a site map beats memory. Education only.
Injection site rotation guide
How injection-site rotation works in practice: the principle of spreading placement, common subcutaneous areas, and using a site map to stay consistent.
How to build a protocol schedule
The concepts behind a research protocol schedule: why frequency tracks half-life, what phases are, and why a defined schedule makes tracking possible.
How to read bloodwork trends over time
Why a single lab value means less than a trend, how biological variation clouds one measurement, and the correlation-not-causation caveat. Education only.
What is the difference between compounded and brand GLP-1?
Compounded versus branded GLP-1 products: what compounding means, why the reconstitution math differs, and the real FDA regulatory context. Education only.
Is compounded semaglutide still legal? (2026 update)
Compounded semaglutide's legal status explained: the FDA drug-shortage exception that allowed it, the 2024–2025 shortage resolutions, and the restricted 2026 picture. Education only.
Are peptides legal?
Are peptides legal? It depends on which peptide and the context. A plain-English 2026 guide to FDA-approved vs research peptides, compounding, and sport rules. Education only.
Is BPC-157 legal?
Is BPC-157 legal? A plain-English look at its US status: not FDA-approved, sold "for research", the 503A compounding decision, and the WADA sport ban. Education only.
Peptide compounding pharmacies, explained
What a peptide compounding pharmacy is, how 503A and 503B compounding differ, and how to tell a legitimate one from the rules alone. Education only, no sourcing.
What is happening with FDA peptide regulation in 2026?
FDA peptide regulation in 2026, explained: the 503A bulk-substances review, the advisory committee, the direction of travel — and how to follow the primary sources yourself. Education only.
BPC-157 doses: what 182 people actually report
First-party data: 244 structured BPC-157 reports from 182 people — the dose distribution by route, the milligram/microgram collision hiding inside it, stacks, and honest evidence context.
SS-31 (elamipretide): what the trial found, and what 117 people actually report
First-party data on SS-31 (elamipretide): 197 structured reports from 117 people describing their own use, set against the completed MMPOWER-3 phase 3 trial and the Barth syndrome approval.
SLU-PP-332 doses: what 133 people actually report
First-party data: 216 structured SLU-PP-332 reports from 133 people. The community splits almost exactly in half over whether this is a microgram or a milligram compound.
MOTS-c: what your body makes, what mice did, and what 202 people actually report
First-party data on MOTS-c: 294 structured reports from 202 people describing their own use, set against the human evidence (endogenous levels, measured) and the mouse evidence (injected, per kilogram). No human trial of injected MOTS-c exists.
Zyra Track is a research and educational utility. Nothing on this page is medical advice, a dosing recommendation, or an endorsement of any compound. We never sell or source compounds and refuse sourcing questions. Consult a qualified clinician for decisions about your health.